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Abstract
Recombinant subunit vaccines are an efficient strategy to meet
the demands of a possible influenza pandemic, because of rapid and
scalable production. However, vaccines made from recombinant
Hemagglutinin (HA) subunit protein are often of low potency,
requiring repeated boosting to generate a sustained immune
response. Previously, we demonstrated improved immunogenicity
of a plant-made H1 Hemagglutinin (HA) vaccine by chemical
conjugation to the surface of the Tobacco Mosaic Virus (TMV)
which is non infectious in mammals. Antigen coated TMV is taken
up by mammalian dendritic cells and is a highly effective antigen
carrier for subunit protein vaccines. In this work, we tested the
effectiveness of a TMV-H5 HA conjugate vaccine. We compared the
TMV-H5 immunogenicity in mice, with and without an oil-in water
squalene adjuvant, to H5N1 virus or HA protein alone, as measured
by anti-H5 IgG titers and Hemagglutination Inhibition (HAI). We then
evaluated the efficacy of the TMV-H5 vaccine by lethal H5N1 virus
challenge in mice. Our results show that a single dose of the TMV-H5
conjugate vaccine is sufficient to generate 40% survival, similar to H5
protein given with adjuvant, or 100% survival after vaccination with
adjuvant, similar to H5N1 virus vaccination.
Keywords: Influenza; H5N1; Nanoparticle; Plant made
pharmaceuticals; Tobacco Mosaic Virus (TMV); Hemagglutinin (HA);
Subunit protein; Vaccination; Dose sparing
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Introduction

Vaccination against influenza A infection has undoubtedly
saved millions of lives, but zoonotic influenza represents a
continuous source of potentially new infectious virus strains,
either by mutation to promote human infections, or by genetic
shift through reassortment with a human seasonal influenza.
Symbiosis Group

Since 1997, H5N1 has emerged as a potentially pandemic
virus from human contact with infectious birds [1], with an
alarmingly high fatality rate of ~53% [2]. Unfortunately the
H5N1 virus continues to generate a high rate of mutation, and
many new clades of virus [3-5]. This is of special concern,
because 1) the strain banked against a possible pandemic may
not be immunologically relevant [6], 2) the poor efficacy of the
current vaccine will require two immunizations (with adjuvant)
to achieve homologous or heterologous immunity in vaccinated
individuals [7, 8], or 3) that it will take months to scale up
embryonated egg-based vaccine production, which may be too
slow to facilitate mass immunization.

Significant progress has been made to rapidly produce
H5N1 vaccines by expression of the Hemagglutinin (HA) protein
as the vaccine agent. HA protein is the main stimulus of virus
neutralization, and can be made independently of the whole
virus. Production is much safer, simpler and faster [9], and H5 HA
immunization generates protective immunity in mice [10], ferrets
[11, 12] and in humans [13-15]. But, H5 HA protein is weakly
immunogenic, and requires boosting and/or adjuvant use for
inducing effective immunity, so immune potency is still an issue.
We have optimized HA formulation by chemically associating H5
HA protein to the surface of, Tobacco Mosaic Virus (TMV), a noninfectious plant virus. TMV is an attractive virus carrier, because
it has the optimal size to promote immune cell uptake [16, 17],
can be made at Kg scale in planta with a minimum of processing
steps, and is not a mammalian pathogen [18]. We have developed
a TMV coat protein variant that expresses a surface exposed
lysine [19] that allows for high density association of HA protein
to the virus surface, using a one step conjugation chemistry [20].
In this study, we have greatly improved the low immunogenicity
of H5 HA subunit vaccination by TMV-H5 conjugation, with
equivalent immune activation potency as an MF-59-like squalene
adjuvant. This could be an important advance in development of
dose-sparing protective HA vaccines that are based on subunit
antigen delivery by virus co-formulation.
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Materials and methods
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Conjugation and Vaccine preparation
Chemical conjugation of an H5 HA1 Fc fusion protein (10003V06H1, Sino Biological Inc.,) to the surface of lysine modified TMV
virus [19], was done as previously described [20]. Conjugation
reactions were considered complete when no free HA protein
was visible by SDS-PAGE. After conjugation, reactive agents
were removed by overnight dialysis against PBS in Slide-a-Lyzer
cartridge (Thermo-Scientific), and the protein quantity was
determined by the Bicinchoninic Acid Assay (BCA;BioRad), and
HA content was quantified by Enzyme Linked Immunosorbent
Assay (ELISA), to normalize the vaccine dose.

Vaccination and immune response evaluation in mice

BALB/c mice (Charles River, CA) were housed at Touro
University according to guidelines established in the Care and
Use of Animals and according to IACUC approved protocols.
Mice were given a 100 – 200 µl subcutaneous (s.c.) injection
of 7.5 μg HA protein (unconjugated), or the equivalent HA as a
15 μg conjugate, with or without a squalene based oil-in-water
emulsion adjuvant AddaVax™ (1:1 ratio; InvivoGen). Inactivated
H5N1 virus was used as a positive control, and pre-immune
serum was used to determine baseline sera titers. Vaccines were
administered on day one and day 30, and sera was collected by
tail vein bleed on days 14 and 28 days post vaccine 1 (pV1) or day
44, 14 days post vaccine 2 (pV2) for ELISA analysis.
ELISA was used to determine serum IgG titers as previously
described [21]. Anti-H5 titers reported in ng/ml were determined
from a standard curve generated by a 3-fold serial dilution of a 10
ng/ml mouse anti-HA monoclonal antibody (DPJY01, BEI #NR19869). Hemagglutinin Inhibition (HAI) titers of the sera were
then determined by the standard microtitration method [22],
with serial 2-fold dilution of serum mixed with 0.5% turkey Red
Blood Cells (RBCs; Innovative Research, Inc.) in sterile phosphate
buffered saline (PBS;Gibco).

H5N1 virus challenge

H5N1 virus challenge studies were conducted under animal
Bio-safety level 3 (ABSL3) conditions and according to St. Jude
Children’s Research Hospital approved institutional procedures
and protocols. Ten week old BALB/c mice were vaccinated once,
using 15 µg H5 protein equivalent, or two times 14 days apart
with 7.5 µg H5 protein equivalent, with or without squalene
based adjuvant. At day 26, serum was collected for ELISA and
HAI analysis, and on day 28, mice were challenged intranasally
with 10xLD50 of highly pathogenic avian A/Vietnam/1203/04,
diluted in 50 µL of PBS, as previously described [23]. Mice were
monitored daily for >25% weight loss, neurologic signs, or motor
dysfunction, and were euthanized according to IACUC approved
procedures.

Results and discussion

TMV-H5 HA conjugation and pilot immunization
As shown in Figure 1, we used EDC/NHS (1-Ethyl-3-(3-
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Figure 1: Preparation of the TMV-H5 conjugate vaccine.
A 1:1 mass ratio of TMV-lysine (T: filled triangle) and H5 HA1 protein
(H5: filled circle; Sino Biologicals #10003-V06H1; homologous to A/
Vietnam/1203/2004) were reacted in the presence of EDC/NHS for
0, 30, 60 or 90 minutes, and then stopped with the addition of 10mM
methylamine. Reactions were dialyzed against PBS, and then 3 µg
protein was separated by an 8-16% gradient SDS-PAGE (BioRad),
compared to Precision Plus molecular weight standard (BioRad).
High molecular weight conjugate product (arrow) and TMV dimers/
mulitmers (asterisks) are seen after 30 minutes, and are not increased
by further incubation time.

dimethylaminopropyl)
carbodiimide/N-hydroxysuccinimide)
conjugation of H5 HA (H5 HA1-Fc protein; Sino Biological Inc.,)
to a lysine modified TMV as previously described [20]. After 30
minutes, both TMV (triangle) and HA (circle) are reduced, and
a high molecular weight aggregate (TMV-H5) accumulates in
the gel above 250 kDa, and in the stack after 8-16% SDS-PAGE
separation (arrow). A TMV dimer and tetramer are also visible
(asterisks).
To assess immune response titers, 7.5 µg of HA equivalent
protein as TMV-H5 conjugate was used to immunize mice (n=3),
with or without a squalene based oil-in-water adjuvant (Sq;
InvivoGen). Inactivated H5N1 virus was also used as a positive
control, and H5 protein given +/-Sq was used to control for HA
immune reactivity without TMV. Mice were tested for anti-HA
IgG 14 and 28 days after a single dose, and at day 44, 14 days
after a boost on day 30. As shown in Figure 2A, all immunized
mice had measureable anti-H5 specific IgG titers after a single
dose of TMV-H5, when compared to an anti-H5 monoclonal
antibody standard (DPJY01, BEI #NR-19869). Only TMV-H5 with
Sq had significantly better immune titers (* p < 0.05) than any
of the other vaccine groups, suggesting synergy in H5 immune
potentiation between TMV and adjuvant. Notably, TMV-H5
had statistically similar immune titers compared to H5 HA
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Figure 2: TMV-H5 vaccine pilot study; IgG titers and HAI. Mice were immunized one time with 7.5 µg of H5 equivalent protein, or H5N1 virus as
a control. At 14 (b1) or 28 (b2) days post vaccine 1 (A/B), serum was collected, and tested for total IgG by ELISA on plates coated with 5ug/ml baculovirus expressed H5 protein (BEI # NR-10510). Serum responses were quantified against a standard curve of 10ng/ml anti-H5 IgG (DPJY01, BEI
#NR-19869), and differences in response are indicated (significant *:p≤0.05;NS:not significantly different). One additional dose was administered at
day 30, and bleed 3 serum responses were measured at day 44 by the same method (C). Relevant H5N1 virus (A/Vietnam/1203/2004) was titered for
turkey RBC agglutination (D). Virus at 4 fold greater than the minimum agglutinating titer was then pretreated with serial dilutions of RDE-treated
serum from study sera. After 1 hour, 0.05% turkey red blood cells were added, and HAI titer was measured as the inverse of the minimum dilution
blocking the formation of RBC agglutination (RBC buttons). TMV vaccination gave titers equivalent to pre-immune sera (not shown).

protein given with squalene (NS; not significantly different),
indicating that TMV provides adjuvant activity equivalent to
that of squalene emulsions [20]. After two weeks (Figure 2B),
the immune response to TMV-H5 Sq nearly doubled (mean 6.3
vs 11.1), suggesting that TMV-HA vaccines may also provide a
depot effect. Two weeks after a second immunization (Figure
2C), TMV-H5 Sq boosted mice had a log increase in IgG titer
(mean 11.1 vs 140.0) which was significantly better than other
vaccine groups (p < 0.001), and all other immune responses were
statistically similar to each other (NS).
Although IgG titers were low for both H5N1 virus and H5 HA
Sq after two immunizations, significant HAI titers (> 40) were
measured for all vaccine groups except HA protein given without
adjuvant (* p < 0.05; Figure 2D), indicating both quantitative and
qualitative boosting of TMV-HA conjugate vaccines.

Immunization and protection from H5N1 viral
challenge

As shown in Figure 3A, mice were immunized following a
similar strategy in the pilot study. Mice (n=10) were vaccinated

with either one dose (15 µg total HA protein) on day 1, or two
doses on days 1 and 14 (7.5 µg each dose, 15 µg total HA protein),
with or without oil-in-water squalene (Sq) adjuvant as indicated.
HA only was not tested in this study due to lack of IgG and HAI
responses in the pilot study. Sera were collected on day 28, and
mice were challenged on day 30 by intranasal administration
of 10xLD50 of A/Vietnam/1203/04. Mice were monitored for
symptoms of infection (weight loss, neurological or behavioral
changes), and euthanized according to IACUC protocols. As
shown in Figure 3B, IgG immune response titers were slightly
different than the pilot, especially in regards to inactivated
H5N1 virus responses, which were much higher than in the
pilot, possibly due to differences in preparations and estimates
of HA content. Another difference, was the low IgG induced by
TMV-HA, after either one or two vaccines. However, after one
dose TMV-HA+Sq induced significantly higher IgG titers than
HA+Sq (p < 0.05) and was not different than inactivated virus
immunization. After two doses, TMV-HA+Sq, HA+Sq and H5N1
virus immunization induced similar levels of IgG. In contrast, HAI
titers (Figure 3C) for TMV-HA were significantly better after two
doses than HA+Sq, with or without squalene adjuvant addition.
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Figure 3: TMV-H5 challenge study; IgG titers and HAI. A. Mice were immunized two times,14 days apart, with 7.5 µg of H5 equivalent protein, or
one time with 15 µg of equivalent H5 protein, using H5N1 virus or PBS as controls. B. At 28, serum was collected, and tested for total IgG by ELISA
on plates coated with 5 µg/ml baculovirus expressed H5 protein (BEI # NR-10510). Serum responses were quantified against a standard curve of
10ng/ml anti-H5 IgG (DPJY01, BEI #NR-19869). C. The minimum agglutinating titer was determined with serial dilutions of RDE-treated serum (as
in Figure 2).

Figure 4: TMV-H5 challenge study; weight loss and survival. Mice were immunized two times,14 days apart, with 7.5 µg of H5 equivalent protein, or one time with 15 µg of equivalent H5 protein, using H5N1 virus or PBS as controls. At day 30, mice were challenged by intranasal delivery
of 10xLD50 H5N1 virus. Mice were weighed every other day, and euthanized if less than 80% of starting weight, or had signs of neurological or behavioral distress. A/C. Weights were plotted as the average +/- the standard error of measurement. B/D. Survival was calculated by Kaplan-Meier
analysis.
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After a single dose, HAI titer was also significantly better in the
TMV-HA+Sq than HA+Sq vaccine group (p < 0.05), but was not
above background (< 40) in the TMV-HA group.

At day 30, mice were challenged with a lethal dose of A/
Vietnam/1203/04, and monitored for weight changes and
survival. After one immunization, TMV-HA+Sq generated
equivalent protection to inactivated H5N1 virus vaccination
(100% of mice) both in terms of weight loss (Figure 4A) and
survival (Figure 4B). Surprisingly, despite low IgG and low HAI
for TMV-HA after one dose (no adjuvant), we measured 40%
survival, equivalent to HA+Sq (Figure 4B), indicating that TMV
provides immune activation activity similar or equal to that of a
squalene-based MF-59-like adjuvant. After two immunizations,
all vaccine groups had statistically similar survival (90-100%;
p > 0.9), irrespective of adjuvant use, and compared to the PBS
control (p < 0.01).

Ongoing studies to further improve TMV-HA formulations
include intranasal administration, to improve mucosal immunity,
multivalent combinations of various TMV-HAs, and additional
adjuvant co-formulations. Preliminary data suggest higher
mean titers of anti-H5 IgG are achieved with TMV-H5 intranasal
dosing, but HAI, microneutralization analysis, cross protection,
and challenge studies will be needed to confirm relevance to
protection, similar to other studies using HA virus-like particles
[24], nanoparticles [25] or virus vaccines [26].
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